CXCL8 and prostate cancer: Subsequently, our group demonstrated that autocrine CXCL8 signaling confers resistance to the DNA-damaging agent oxaliplatin, the death receptor agonist TRAIL and anti-metabolites in prostate cancer cells [79,80,81].